IBDoc Canadian User Performance Evaluation.

Inflammatory bowel disease monitoring relies on biomarkers to assess mucosal inflammation. Fecal calprotectin is a widely used indicator for this purpose. However, traditional methods require patients to submit stool samples to laboratories. This process can be inconvenient and may reduce adherence. Prior research has shown that fecal calprotectin is both sensitive and specific for IBD. Yet, no prior work had resolved the issue of patient compliance with sample collection and return. That uncertainty drove the development of home-based alternatives. No prior studies had evaluated the usability of such a test in a Canadian context. This gap motivated the design of a study to assess a home-based fecal calprotectin test. The goal was to determine whether this method could match traditional lab results while improving user experience.

The study aimed to assess the usability and accuracy of a home-based fecal calprotectin test called IBDoc. The researchers sought to determine if patients found the test easy to use and if it produced results comparable to standard lab methods. They wanted to evaluate whether this home-based approach could improve patient adherence. The motivation was to address the limitations of traditional stool sample submission. The study focused on patients with Crohn's disease or ulcerative colitis. The researchers also aimed to compare IBDoc results with those from ELISA-based measurements. They wanted to measure both quantitative and qualitative agreement. The ultimate goal was to support the adoption of a treat-to-target strategy in IBD management.

The study enrolled participants from three Canadian tertiary care centers. Patients with a diagnosis of Crohn's disease or ulcerative colitis were included. Each participant used the IBDoc home test to measure fecal calprotectin. They also submitted a stool sample for ELISA-based testing. A questionnaire assessed the ease of use and willingness to adopt the home test. The IBDoc results were compared with the ELISA measurements. The comparison included both quantitative and qualitative assessments. The study evaluated overall agreement and the presence of false positives or negatives.

Sixty-one participants completed the study, including 29 with Crohn's disease and 32 with ulcerative colitis. Seventy-nine percent of patients found the IBDoc easy to use. Eighty-five percent strongly agreed to using the home kit in the future. The comparison between IBDoc and ELISA showed 88% agreement across all values. No false positives or negatives were observed in the qualitative analysis. The home test produced results that closely matched the lab-based measurements. The usability scores were high across all demographic groups. The study demonstrated strong concordance between the two testing methods. These findings suggest the IBDoc is both accurate and user-friendly.

The IBDoc home-based fecal calprotectin test is acceptable to patients and shows strong agreement with ELISA results. The study found no false positives or negatives when using qualitative comparison. The high usability scores suggest that patients are likely to adopt this method. The researchers propose that this test can support a treat-to-target approach in IBD management. The results suggest that the home test could improve long-term outcomes for patients. The study supports the potential of IBDoc to enhance patient quality of life. The authors suggest that this method may increase adherence to monitoring regimens. The findings align with the goal of improving IBD care through accessible diagnostics.